Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28328685 | 0.93 | CYP19A1 (0.86) | CYP19A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL28533317 | 0.89 | CYP19A1 (0.97) | CYP19A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL10044916 | 0.88 | CYP19A1 (1.00) | CYP19A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL2193998 | 0.88 | CYP19A1 (1.00) | CYP19A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL16206208 | 0.86 | CYP19A1 (0.82) | CYP19A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL15014123 | 0.86 | CYP19A1 (0.76) | CYP19A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL2194279 | 0.86 | CYP19A1 (0.77) | CYP19A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL16216237 | 0.85 | CYP19A1 (0.74) | CYP19A1MAOAMAOBHSP90AB1 | |
| SCHEMBL15795458 | 0.83 | CYP19A1 (0.71) | CYP19A1MAOAMAOBNPC1RAB9A | |
| SCHEMBL29025354 | 0.82 | CYP19A1 (0.69) | CYP19A1MAOAMAOBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011527628-A | — | — | 2011-11-04 | — | — | JP | claimed |
| WO-2010005127-A2 | HETEROGENEOUS COPPER NANOCATALYST AND MANUFACTURING METHODS THEREOF | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2010-01-14 | — | — | WO | claimed |
| WO-2023141534-A1 | AGENTS THAT TARGET TELOMERASE REVERSE TRANSCRIPTASE (TERT) FOR TREATING CANCER AND SENSITIZING CANCER CELLS TO GENOTOXIC THERAPY | NORTHWESTERN UNIVERSITY (US) | 2023-07-27 | — | — | WO | disclosed |
| US-9428472-B2 | Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives | GEORGETOWN UNIVERSITY (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150259305-A1 | CATALYTIC REACTION | NATIONAL TSING HUA UNIVERSITY (TW) | 2015-09-17 | — | — | US | disclosed |
| US-20150259305-A1 | CATALYTIC REACTION | NATIONAL TSING HUA UNIVERSITY (TW) | 2015-09-17 | — | — | US | disclosed |
| US-8907105-B1 | 1,2,3-triazolium ionic liquids | U.S. DEPARTMENT OF ENERGY (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906135-B1 | Method of purifying a gas stream using 1,2,3-triazolium ionic liquids | U.S. DEPARTMENT OF ENERGY (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140296310-A1 | METHODS OF TREATING BACTERIAL INFECTIONS WITH 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | GEORGETOWN UNIVERSITY (US) | 2014-10-02 | — | — | US | disclosed |
| US-20110251193-A1 | 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | WICHITA STATE UNIVERSITY (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2010005127-A2 | HETEROGENEOUS COPPER NANOCATALYST AND MANUFACTURING METHODS THEREOF | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296310-A1 | METHODS OF TREATING BACTERIAL INFECTIONS WITH 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | VIP, VIL1, BAK1 | CYP19A1 3556/4885MAOA 3437/4885MAOB 2416/4885 |
| US-20150259305-A1 | CATALYTIC REACTION | HAO2, CAT, HAAO | CYP19A1 358/4885MAOA 137/4885MAOB 303/4885 |
| US-20110251193-A1 | 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | HAVCR2, ERG28, ZC3HAV1 | CYP19A1 920/4885MAOA 2122/4885MAOB 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.